Identification of DNASE1L3 as a novel biomarker of clinical stage in liver hepatocellular carcinoma
Our results identified <i>DNASE1L3</i> as a promising tissue biomarker. Loss of <i>DNASE1L3</i> is indicative of advanced and aggressive LIHC, and therefore its expression may offer complementary information to current staging systems to improve prognostic assessment.
Authors
- Tong Wu (ORCID: https://orcid.org/0009-0004-5980-7754)
- S. Chen
- Yue Xu (ORCID: https://orcid.org/0000-0001-7672-9170)
- D. Robert Lu (ORCID: https://orcid.org/0009-0009-0859-9197)
- Shuying Xie
- Ruixi Li
- Weina Xue
Institutions
- Guiyang Medical University (CN)
- University of Toronto (CA)
- State Administration of Traditional Chinese Medicine of the People's Republic of China (CN)
Publication Details
- Journal
- Frontiers in Molecular Biosciences
- Published
- 2026-01-12
- DOI
- https://doi.org/10.3389/fmolb.2025.1681888
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Guizhou Science and Technology Department